Market Place
Sourcing Support
Zevra Therapeutics Reveals Q1 2026 Financial Results Call
22 Apr 2026 //
GLOBENEWSWIRE
Fierce Madness Drug Name Tournament 2026—Round Of 32 Voting Open
20 Mar 2026 //
FIERCE PHARMA
OPEX® To Present Warehouse Automation Solutions At MODEX 2026
17 Mar 2026 //
PHARMIWEB
Zevra Reports Fourth Quarter And Full Year 2025 Financial Results
09 Mar 2026 //
GLOBENEWSWIRE
Zevra Therapeutics Reveals Q4 & Full Year 2025 Financial Results
02 Mar 2026 //
GLOBENEWSWIRE
Zevra Therapeutics To Present At Citizens Life Sciences Conf
25 Feb 2026 //
GLOBENEWSWIRE
Zevra Therapeutics to Ring Nasdaq Bell Feb. 9
02 Feb 2026 //
GLOBENEWSWIRE
Zevra Therapeutics Presents At J.P. Morgan Healthcare Conference
08 Jan 2026 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Inducement Grants Under Nasdaq LR
12 Dec 2025 //
GLOBENEWSWIRE
Zevra Reports Q3 2025 Financial Results & Update
05 Nov 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Joins Guggenheim Healthcare Innovation Conf
29 Oct 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Reveals Q3 2025 Financial Results Call
27 Oct 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Inducement Grants Under Nasdaq LR
06 Oct 2025 //
GLOBENEWSWIRE
Zevra To Present Miplyffa Data at ICIEM 2025 Congress
28 Aug 2025 //
GLOBENEWSWIRE
Zevra Therapeutics to Present at Investor Conferences
26 Aug 2025 //
GLOBENEWSWIRE
Zevra`s Q2 2025 Financial Results and Corporate Update
12 Aug 2025 //
GLOBENEWSWIRE
Zevra Therapeutics join Canaccord Genuity 45th Annual Conference
06 Aug 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Sets Q2 2025 Financial Results Call Details
04 Aug 2025 //
GLOBENEWSWIRE
Zevra Announces 2025 Annual Meeting Results
29 May 2025 //
GLOBENEWSWIRE
Zevra Reports Q1 2025 Financial Results and Corporate Update
13 May 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Details Q1 2025 Financial Results Call
06 May 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Files Preliminary Proxy
31 Mar 2025 //
GLOBENEWSWIRE
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results
11 Mar 2025 //
GLOBENEWSWIRE
Zevra Launches ‘Learn NPC’ Awareness Campaign For Niemann-Pick C
28 Feb 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Sells Rare Pediatric Disease Voucher for $150M
27 Feb 2025 //
GLOBENEWSWIRE
Zevra to Report Q4 & Full 2024 Financial Results
26 Feb 2025 //
GLOBENEWSWIRE
Zevra to Participate at Upcoming Investor Conferences
24 Feb 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Reports Q3 2024 Financial Results & Updates
12 Nov 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Report Q3 2024 Results on Nov 12, 2024
31 Oct 2024 //
GLOBENEWSWIRE
NUCDF And Zevra Launch Check Ammonia Campaign For Disorders
09 Oct 2024 //
GLOBENEWSWIRE
Orsini Named Exclusive Specialty Pharmacy for MIPLYFFA™ in U.S.
24 Sep 2024 //
PR NEWSWIRE
Relief Therapeutics Announces $2 Million Milestone
20 Sep 2024 //
ACCESSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Reports Q2 2024 Results And Corporate Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock
09 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics To Present At Canaccord Genuity Growth Conference
07 Aug 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
30 Jul 2024 //
GLOBENEWSWIRE
Zevra Announces FDA Meeting To Review Arimoclomol For Niemann-Pick
09 Jul 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Expands Executive Leadership Team
25 Jun 2024 //
GLOBENEWSWIRE
Zevra Transitions To Orsini As Provider For OLPRUVA® In Urea Cycle Disorders
18 Jun 2024 //
GLOBENEWSWIRE
Zevra`s KP1077 Shows Positive Phase 2 Results In Idiopathic Hypersomnia
03 Jun 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Events
09 May 2024 //
GLOBENEWSWIRE
Zevra Q1 2024 Financials, Corporate Updates
08 May 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
01 May 2024 //
GLOBENEWSWIRE
Zevra CEO`s Shareholder Letter on 2023 Progress & 2024 Outlook
29 Apr 2024 //
GLOBENEWSWIRE
Zevra: Arimoclomol Long-Term NPC Safety, Efficacy At SIMD
15 Apr 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Refinances Debt, Secures Up to $100M Capital
10 Apr 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Zevra Announces Top-Line Data from the Phase 2 Trial of KP1077 for IH
26 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Conference
25 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol
04 Mar 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Conferences
28 Feb 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Conference
06 Feb 2024 //
GLOBENEWSWIRE
Zevra Appoints Biopharma Executive Alvin Shih to the Board of Directors
23 Jan 2024 //
GLOBENEWSWIRE
Zevra Receives FDA Acceptance of Resubmission of NDA for Arimoclomol
08 Jan 2024 //
GLOBENEWSWIRE
Zevra Appoints Global Medical Leader, Adrian Quartel as Chief Medical Officer
04 Jan 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Resubmission of Arimoclomol NDA to FDA
27 Dec 2023 //
GLOBENEWSWIRE
Zevra Therapeutics Acquires Acer Therapeutics
20 Nov 2023 //
CONTRACT PHARMA
Zevra Therapeutics Completes Acquisition of Acer Therapeutics
20 Nov 2023 //
GLOBENEWSWIRE
